Anova Enterprises, Inc. announced a partnership with Dizal Pharmaceuticals (Dizal) to accelerate the development of DZD9008 for patients with EGFR Exon20ins mutant NSCLC. Dizal is a commercial-stage biopharmaceutical company focused on the discovery and development of differentiated therapeutics for the treatment of cancer and immunological diseases. Dizal are evaluating DZD9008 in a Phase III study in a first-line setting and a Phase II study in a recurrent setting.

EGFR Exon20ins occur in about 2% patients with NSCLC. No target therapy has gained full approval for the treatment. Chemotherapy is the most commonly used in the first-line setting, but the treatment?s efficacy is not optimal.

Therefore, there is an unmet medical need to develop more effective therapy.